

NON-BINDING CONVENIENCE TRANSLATION

of a

Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014 published 24-Jul-2018 / 13:16 CET/CEST

Elanix Biotechnologies AG resolves a capital increase of up to 10 percent equaling 2.1 Mio EUR with indirect subscription rights using the authorized capital

THE INFORMATION CONTAINED IN THIS RELEASE IS NOT TO BE PUBLISHED OR FORWARDED IN OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA OR JAPAN OR ANY OTHER COUNTRY WHERE SUCH A DISTRIBUTION OR PUBLICATION WOULD BE UNLAWFUL

Berlin, July 24 2018 - The Management Board of Elanix Biotechnologies AG ("the Company") has resolved under the partial use of the authorized capital 2015 to increase the company's share capital from EUR 7,779,139.00 by up to EUR 777,910.00 to up to EUR 8,557,049.00 by issuing up to 777,910 new no-par value bearer shares ("New Shares") in exchange for cash contributions. The capital increase should be legally designed in such a way that it does not require a securities prospectus under German law (§§ 3 (2) no. 5, 4 (2) WpPG in the new version of 21 July 2018).

The new shares will be offered to company shareholders against contribution in cash in the ratio 10:1 (ten existing shares allow a subscription of one new share). The subscription period is expected to run from and including 27 July 2018 to and including 10 August 2018. The subscription price is EUR 2.75 per new share, based on the average closing share price of the last five trading days at Frankfurt Stock Exchange before fixing the final issued share price minus 10% discount. In addition, shareholders can register for so-called supplement subscriptions ("over-subscription") through their depository bank but will not automatically be guaranteed an allotment of shares. Any shares not purchased within the course of the pre-emptive rights offering will be offered to selected investors in the form of a private placement. The share price for the private placement will be, at minimum, the subscription price. The capital increase will only be executed if minimum 300.000 shares will be subscribed.

The up to 777,910 New Shares are entitled to dividends for the 2018 financial year. The exact number of New Shares to be issued will be determined by the Management Board with the approval of the Supervisory Board in due course. The planned strengthening of the equity base should enable business activities to be expanded on a stable foundation. In addition, the company's growth is to be accelerated by strengthening the product portfolio as well as expanding distribution and distribution channels.

More detailed information about the capital increase will be provided in the pre-emptive rights offering expected to be published in the electronic Federal Gazette on 27 July. No securities prospectus will be published with this capital increase. The Management Board will inform about more details of the capital increase in due course.

Tomas Svoboda, CEO

Contacts

Elanix Biotechnologies
Tomas Svoboda
Tel: +41 (0)22 363 66 40
investor.relations@elanix-bt.com

About Elanix

Elanix develops and commercializes tissue regeneration products for acute wound care, dermatological and gynecological applications, and provides services in cell technologies. The company was founded in 2012 as a spin-out from the University Hospital of Lausanne (CHUV), Switzerland, to commercialize a patented human progenitor cell technology. Progenitor cells are fully differentiated yet immunologically neutral cells that are very potent inducers of tissue growth and healing. Elanix owns GMP certified Master and Working human cell banks with vast quantities of cells.

Elanix has registered headquarters in Berlin, Germany, with offices in Wiesbaden, Germany and Nyon, Switzerland. It is listed in the Regulated Market on the Frankfurt Stock Exchange under the symbol ELN.F. For more information and updates, visit www.elanixbiotechnologies.com

Disclaimer

This publication may not be published, distributed or transmitted, directly or indirectly, in the United States of America (including its territories and possessions), Canada, Japan or Australia or any other jurisdiction where such an announcement could be unlawful. The distribution of this announcement may be restricted by law in certain jurisdictions and persons who are in possession of this document or other information referred to herein should inform themselves about and observe any such restrictions. Any failure to comply with these restrictions may constitute a violation of the securities laws of any such jurisdiction.

This publication does not constitute an offer of securities for sale or a solicitation of an offer to purchase securities of Elanix Biotechnologies AG in the United States of America, Germany or any other jurisdiction. In connection with this transaction there will be no publication of a securities prospectus.

Neither this announcement nor anything contained herein shall form the basis of, or be relied upon in connection with, any offer or commitment whatsoever in any jurisdiction. The securities referred to herein may not be offered or sold in the United States of America in the absence of registration or an exemption from registration under the U.S. Securities Act of 1933, as amended (the "Securities Act"). The securities of Elanix Biotechnologies AG have not been, and will not be, registered under the Securities Act.

This announcement does not constitute a recommendation concerning the placement of securities described in this announcement. Investors should consult a professional advisor as to the suitability of the Placement for the person concerned.

In the United Kingdom, this document is only directed at persons who (i) are investment professionals falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (as amended) (the "Order") or (ii) are persons falling within Article 49(2)(a) to (d) of the Order (high net worth companies, unincorporated associations, etc.) (all such persons together being referred to as "Relevant Persons"). This document must not be acted on or relied on by persons who are not Relevant Persons. Any investment or investment activity to which this document relates is available only to Relevant Persons and will be engaged in only with Relevant Persons.

In member states of the European Economic Area which have implemented the Prospectus Directive (each, a "Relevant Member State"), this announcement and any offer, if made subsequently, is directed exclusively at persons who are "qualified investors" within the meaning of the Prospectus Directive. For these purposes, the expression "Prospectus Directive" means Directive 2003/71/EC (and amendments thereto, including the Directive 2010/73/EU), and includes any relevant implementing measure in the Relevant Member State.

No action has been taken that would permit an offering of the securities, a purchase of the

securities or possession or distribution of this announcement in any jurisdiction where action for that purpose is required. Persons into whose possession this announcement comes are required to inform themselves about and to observe any such restrictions.

This announcement also does not constitute a prospectus within the meaning of the EU Directive 2003/71/EC of the European Parliament and of the Council of 4 November 2003 as amended ("Prospectus Directive").

Forward-looking statements

This publication may contain certain forward-looking statements concerning the Company and its business. Such statements involve certain risks, uncertainties and other factors which could cause the actual results, financial condition, performance or achievements of the Company to be materially different from those expressed or implied by such statements. Readers should therefore not place undue reliance on these statements, particularly not in connection with any contract or investment decision. The Company disclaims any obligation to update these forward-looking statements.